Journal Logo

Simultaneous Sessions I: Indolent and mantle-cell non-Hodgkin lymphoma – Clinical

S104 THE BRAF INHIBITOR VEMURAFENIB COMBINED WITH RITUXIMAB PRODUCES A HIGH RATE OF DEEP AND DURABLE REMISSIONS IN RELAPSED OR REFRACTORY HAIRY CELL LEUKEMIA: UPDATED RESULTS OF A PHASE-2 TRIAL

Tiacci, E.1; De Carolis, L.1; Simonetti, E.1; Zaja, F.2; Capponi, M.1; Ambrosetti, A.3; Lucia, E.4; Antolino, A.5; Pulsoni, A.6; Ferrari, S.7; Zinzani, P. L.8; Rigacci, L.9; Gaidano, G.10; Della Seta, R.11; Frattarelli, N.12; Falcucci, P.13; Visani, G.14; Foà, R.6; Falini, B.1

Author Information
doi: 10.1097/01.HS9.0000558636.55215.ad
  • Free

Abstract

Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association.